<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02716233</url>
  </required_header>
  <id_info>
    <org_study_id>AOM10205</org_study_id>
    <nct_id>NCT02716233</nct_id>
  </id_info>
  <brief_title>A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents</brief_title>
  <acronym>CAALL-F01</acronym>
  <official_title>A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A still major question in the field of acute lymphoblastic leukemia (ALL) in children - an
      extremely heterogeneous disease though curable in 80-90% of children and 70-80% of the
      adolescents - is the optimal use of L-asparaginase (ASNase). It is known that administering
      ASNase results in the depletion of asparagine circulating in the blood, which starves the
      leukemic cells and results in their death. But indeed the use of ASNase varies between
      protocols considering the different brands, the dose and the administration modalities.
      Oncaspar (PEGylated E. coli asparaginase, pegaspargase) was thus developed with the goal of
      reducing the immunogenicity of the native ASNase.

      This is a French prospective multicentric cohort study of children and adolescents with ALL,
      stratified on (i) the type of ALL ( B vs T) and (ii) the anticipated risk (stratified in 3
      groups for childhood B-cell precursor (BCP)-ALL and 2 groups for T-cell ALL).

      It aims to answer to two different issues:

        1. Randomized question: what is the best way to administer pegaspargase? A cohort of
           children and adolescents with standard or medium risk ALL will be randomized to receive
           during induction either one infusion of ONCASPAR® 2500 IU/m2 at D12 or two infusions of
           ONCASPAR® at 1250 IU/m2 each at D12 and D26. Patients will then receive 2500 IU/m2 or
           1250 IU/m2 per dose during consolidation and delayed intensification according to the
           initial arm of randomization.

        2. Non randomized question: In the High/Very High Risk groups, a non randomized
           intensification of the scheme of asparaginase administration is proposed during
           induction therapy: 2 infusions of 2500 IU/m2/day (D12 and D26) will be administered. All
           patients will receive 2500 IU/m2 per dose during consolidation and delayed
           intensifications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adequate (&gt; 100 IU/L) asparaginase activity measured in the plasma at day 33 of induction therapy</measure>
    <time_frame>Day 33</time_frame>
    <description>asparaginase activity &gt; 100 IU/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of directly asparaginase-related severe toxicities (Grade ≥ 3 as assessed by CTCAE v4.0) observed during induction therapy</measure>
    <time_frame>Between Day 12 of induction and Day 8 of consolidation</time_frame>
    <description>Incidence of severe toxicities (Grade ≥ 3) directly asparaginase-related (CNS thrombosis, pancreatitis, anaphylaxis, and hyperbilirubinemia) between Day 12 and Day 49 of treatment and anyway before Day 8 of consolidation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of asparagine depletion measured in plasma by a concentration below the Limit of Quantification (LOQ) of 0.4 micromol/L</measure>
    <time_frame>Day 33 of induction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adequate (&gt; 100 IU/L) asparaginase activity measured in the plasma at day 40 of induction therapy</measure>
    <time_frame>Day 40 of induction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of asparagine depletion measured in plasma by a concentration below the Limit of Quantification (LOQ) of 0.4 micromol/L</measure>
    <time_frame>Day 40 of induction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antibodies against asparaginase, measured in serum</measure>
    <time_frame>Day 4 of delayed intensification</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of silent inactivation</measure>
    <time_frame>First 6-9 months</time_frame>
    <description>Silent inactivation or subclinical hypersensitivity is defined as a plasma PEGasparaginase activity level &lt;100 IU/L at day 7+/- 1 or &lt;20 IU/L at day 14 +/- 11 after administration in a patient without clinical symptoms of allergy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients without switch to Erwinia asparaginase</measure>
    <time_frame>First 6-9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients receiving more than 95% of the intended dose of asparaginase</measure>
    <time_frame>First 6-9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphological Complete Remission (CR) rates</measure>
    <time_frame>Day 35-Day 42</time_frame>
    <description>Assessed on the whole population or on subgroups (B-Lineage ALL, T-cell ALL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Residual Disease (MRD)</measure>
    <time_frame>Day 35-Day 42, Day 65-Day 105</time_frame>
    <description>MRD will be assessed by Ig/T cell receptor (TCR)-based real-time quantitative (RQ)-polymerase chain reaction (PCR), assessed on the whole population or on subgroups (B-Lineage ALL, T-cell ALL).
Assessed on the whole population or on subgroups (B-Lineage ALL, T-cell ALL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of relapses</measure>
    <time_frame>5 years</time_frame>
    <description>Assessed on the whole population or on subgroups (B-Lineage ALL, T-cell ALL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of relapse according to site of relapse</measure>
    <time_frame>5 years</time_frame>
    <description>Bone-Marrow (BM) relapses, central nervous system (CNS) relapses, gonadal relapses, combined relapses.
Assessed on the whole population or on subgroups (B-Lineage ALL, T-cell ALL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All other adverse events related to asparaginase</measure>
    <time_frame>within the first 7 weeks (Day 49) of treatment and anyway before Day 8 of consolidation</time_frame>
    <description>Drug-induced hyperglycemia or diabetes, coagulopathy, allergy Non CNS thrombosis Grade 1-2 Adverse Events (AE): pancreatitis, hyperbilirubinemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late adverse events related to asparaginase</measure>
    <time_frame>after Day 49 of induction or anyway at Day 8 of consolidation or after</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1578</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pegaspargase 2500 IU/m2 x 1: infusion of a conventional dose of pegaspargase during induction therapy: 2500 IU/m2x1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pegaspargase 1250 IU/m2 x 2: fractionation of the 2500 IU/m2 pegaspargase dose in two infusions of 1250 IU/m2 each</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaspargase 1250 IU/m2 x 2</intervention_name>
    <description>only for ALL of standard risk and medium risk</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>ONCASPAR 1250 IU/m2 x 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaspargase 2500 IU/m2 x 1</intervention_name>
    <description>only for ALL of standard risk and medium risk</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>ONCASPAR 2500 IU/m2 x 1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ALL L1 or L2

          -  B-lineage or T- lineage ALL

        Exclusion Criteria:

          -  L3 (Burkitt's leukemia)

          -  Mixed Phenotype Acute Leukemia (WHO criteria).

          -  Infant ALL (age ≤ 365 days)

          -  Philadelphia (Ph)+/Breakpoint Cluster region (BCR)-Abelson (ABL) ALL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>André Baruchel, MD</last_name>
    <phone>+33 1 40 03 53 88</phone>
    <email>andre.baruchel@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yves Bertrand, MD</last_name>
    <phone>+33 4 69 16 65 70</phone>
    <email>yves.bertrand@ihope.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Devoldere, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Pellier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline Simon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Perel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liana Carausu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Odile Minckes, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justyna Kanold, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elodie Colomb, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Plantaz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Françoise Mazingue, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Oudot, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu-Ihope</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Bertrand, MD</last_name>
      <email>yves.bertrand@ihope.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gérard Michel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Sirvent, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudine Schmitt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Thomas, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Simon Rohrlich, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Boissel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud Petit, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>André Baruchel, MD</last_name>
      <email>andre.baruchel@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric Millot, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie Gordes-Grosjean, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rennes</city>
        <zip>35203</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginie Gandemer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale Schneider, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine Thouvenin-Doulet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Lutz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geneviève Plat, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHu</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale Blouin, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2016</study_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

